Table 1.
Characteristics of Allogeneic HSCT Recipients (N=328) and Their Grafts.
| Characteristics | N | (%) |
|---|---|---|
| Age at Transplantation | ||
| 18–39 Years | 108 | (32.9) |
| 40–64 Years | 191 | (58.2) |
| 65–75 Years | 29 | (8.8) |
| Stage of Disease | ||
| Early | 151 | (46.0) |
| Intermediate | 74 | (22.6) |
| Late | 103 | (31.4) |
| Karnofsky Score at HSCT | ||
| Good (90% or 100%) | 203 | (61.9) |
| Poor (70% or 80%) | 17 | (5.2) |
| Score Unavailable | 108 | (32.9) |
| Ethnicity | ||
| Non-Hispanic White | 206 | (62.8) |
| Hispanic White | 76 | (23.2) |
| Asian | 41 | (12.5) |
| African-American | 5 | (1.5) |
| Body Mass Index | ||
| 18–<21 | 34 | (10.4) |
| 21–<25 | 101 | (30.8) |
| 25–<30 | 111 | (33.8) |
| 30–48 | 82 | (25.0) |
| Type of Donor | ||
| HLA-Matched Sibling | 191 | (58.2) |
| HLA-Matched Unrelated | 137 | (41.8) |
| CMV Serostatus of | ||
| Donor (D)/Recipient (R) | ||
| D+/ R+ | 163 | (49.7) |
| D+/R− | 53 | (16.2) |
| D−/R+ | 74 | (22.6) |
| D−/R− | 38 | (11.6) |
| Sex of Donor / Recipient | ||
| D Male/ R Male | 104 | (31.7) |
| D Male / R Female | 94 | (28.7) |
| D Female / R Male | 64 | (19.5) |
| D Female / R Female | 66 | (20.1) |
| Intensity of Conditioning * | ||
| Myeloablative, TBI | 156 | (47.6) |
| Myeloablative, BuCy | 19 | (5.8) |
| Reduced Intensity | 153 | (46.7) |
| GVHD Prophylaxis † | ||
| Tacro + Siro | 179 | (54.6) |
| Tacro + Siro + Mini MTX | 50 | (15.2) |
| Tacro + Mini MTX | 33 | (10.1) |
| Cyclosporin with MTX and/or Mycophenolate Mofetil | 66 | (20.1) |
*
TBI = Total Body Irradiation, BuCy = Busulfan + Cyclophosphamide
†
Tacro = Tacrolimus, Siro = Sirolimus, MTX = methotrexate